BioLife Solutions Inc (BLFS) Narxning foydaga nisbati
Hujayra terapiyasi sektoridagi uzoq muddatli pasayishga qaramay, BioLife Solutions, Inc. (BLFS) o'sish bosqichiga kirmoqda. Ichki barqarorlik FDA tomonidan tasdiqlangan vositalarning yopiq ekotizimiga asoslangan bo'lib, bu yetkazib beruvchini almashtirishni kritik darajaga olib keladi. P/E koeffitsiyenti tarixi baholash dinamikasini namoyish etadi, bunda parametr qiymati 40.30 ga tengdir. Strategik boshqaruv kompaniyaning butun sanoat uchun biomateriallar logistikasidagi asosiy bo'g'in sifatidagi maqomini mustahkamlaydi.
BioLife Corp (BLFS) kompaniyasining tahliliy kesimlari
- bozor narxi va tahlilchilarning maqsadli narxlari:
- bozor kapitallashuvi tafsilotlari:
- balans kapitallashuvi haqida ma'lumot:
- qarzlar va to'lov qobiliyati haqida ma'lumot:
Qarzning kapitalga nisbati BioLife Solutions, Inc.|BLFS - Uzoq muddatli qarzning o'z kapitaliga nisbati|Qisqa muddatli qarzdorlikning kapitalga nisbati BioLife|BLFS - Kompaniya qarzlari|Sof aktivlarga qarzlar BioLife Solutions, Inc.|BLFS - Kompaniyaning uzoq muddatli qarzi|Qisqa muddatli qarz BioLife Solutions|Tezkor likvidlik biolifesolutions.com
- foyda va bozor multiplikatorlari tafsilotlari:
BLFS - Sof daromad|Prognoz qilingan kelajakdagi foyda BioLife Solutions, Inc.|BLFS - Narx-foyda koeffitsiyenti|Kapitalizatsiyaning kelajakdagi foydaga nisbati BioLife Solutions Inc|BLFS - PEG multiplikatori|Kompaniyaning to‘liq qiymatining amortizatsiyadan oldingi operatsion foydaga nisbati BioLife Solutions, Inc.|BLFS - Foizlar, soliqlar va eskirish to'lanishidan oldingi foyda|So'nggi o'n ikki oy davomida bitta aksiya uchun sof foyda BioLife Solutions|BLFS - So'nggi o'n ikki oy davomida bir aksiya uchun foyda|So'nggi 12 oy davomida bir aksiya uchun foydaning yillik o'sishi biolifesolutions.com|BLFS - Joriy yilda bir aksiya uchun foyda o'sishi|Keyingi yil uchun bir aksiya uchun foyda o'sishining konsensus prognozi BioLife Solutions, Inc.
Kompaniyaning har tomonlama tahlili:BioLife Solutions, Inc.
P/E koeffitsiyenti biznesning bozor qiymatini uning sof foydasiga nisbatan aks ettiradi, bu esa investorga kelajakdagi daromadlar uchun to'langan premiumni baholash va aktivni soha hamkasblari bilan solishtirish imkonini beradi. Kompaniyaning taxminiy P/E koeffitsiyentini tahlil qilish orqali BioLife Solutions, Inc. (BLFS) ning regenerativ tibbiyot va hujayra terapiyasi segmentidagi muhim logistika operatori sifatidagi investitsiya jozibadorligini aniqlash mumkin.
Raqobatdosh kompaniyalar tahlili
Kapitalizatsiyaning foydaga nisbati Tempus AI Inc TEM|Narxning foydaga nisbati Qiagen (QGEN)|Narxning foydaga nisbati IONS (Ionis Pharmaceuticals, Inc.)|P/E multiplikatori RGEN (Repligen Corp.)|Biznesning o‘zini qoplash muddati Avidity Corp (RNA)|CRISPR Therapeutics AG - P/E multiplikatori|Kapitalizatsiyaning sof foydaga nisbati WGS|RARE: P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati Beam Therapeutics Inc (BEAM)|Narx-foyda koeffitsiyenti SRPT|TWST: Kompaniya qiymatining sof foydaga nisbati|Narxning foydaga nisbati 10x Genomics, Inc. (TXG)|Biznesning o‘zini qoplash muddati intelliatx.com|Narxning foydaga nisbati Stoke Therapeutics, Inc. STOK|Wave Life Sciences Ltd (WVE) - Kapitalizatsiyaning foydaga nisbati|MAZE - Narxning foydaga nisbati|SION: Narxning foydaga nisbati|PRME (Prime Medicine, Inc.) - Narx-foyda koeffitsiyenti|tayshagtx.com (TSHA) - P/E multiplikatori|Narx-foyda koeffitsiyenti QURE|MGTX (MeiraGTx Holdings) - Bozor narxining sof foydaga nisbati|P/E multiplikatori RGNX|Biznesning o‘zini qoplash muddati Solid Corp|Narxning foydaga nisbati Ocugen, Inc. OCGN|pacb.com (PACB) - Kapitalizatsiyaning foydaga nisbati|BNTC - Narxning foydaga nisbati|DSGN (Design Therapeutics Inc) - Narx-foyda multiplikatori|Rocket Pharmaceuticals Inc (RCKT) - Narxning foydaga nisbati|FDMT - Biznesning o‘zini qoplash muddati|Narx-foyda koeffitsiyenti LXEO|KRRO: Kompaniya qiymatining sof foydaga nisbati|P/E multiplikatori EDIT|Biznesning o‘zini qoplash muddati Silence Therapeutics PLC|Narxning foydaga nisbati ProQR Therapeutics PRQR|CDXS: Narx-foyda multiplikatori|Sangamo Therapeutics - P/E multiplikatori|Nautilus Biotechnology (NAUT) - Narx-foyda koeffitsiyenti|MGX (Metagenomi) - Narx-foyda koeffitsiyenti|DTIL - Biznesning o‘zini qoplash muddati|GBIO (Generation Bio Co) - P/E multiplikatori|Narxning foydaga nisbati BOLD|Narxning foydaga nisbati Exicure, Inc. (XCUR)|Narxning foydaga nisbati IMNN (imunon.com)|P/E multiplikatori PHIO (Phio Pharmaceuticals Corp.)|MBIO (Mustang Bio Inc) - Kapitalizatsiyaning sof foydaga nisbati|RNAZ - Narxning foydaga nisbati|Biznesning o‘zini qoplash muddati Bionano Genomics, Inc. BNGO|APDN: P/E multiplikatori|Narx-foyda multiplikatori BLUE|Narxning foydaga nisbati ImmunoPrecise Antibodies Ltd|Narx-foyda multiplikatori OMGA (Omega Therapeutics Inc)|P/E multiplikatori OMIC|P/E multiplikatori Regulus (RGLS)|P/E multiplikatori SYRS (Syros Pharmaceuticals)|telesisbio.com - Narxning foydaga nisbati|TRACON Pharmaceuticals, Inc. - P/E multiplikatori|Biznesning o‘zini qoplash muddati Unity Biotechnology Inc. UBX
